These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31738427)

  • 41. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
    Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
    Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Diagnosis and therapy of tumors with NTRK gene fusion].
    Stenzinger A; van Tilburg CM; Tabatabai G; Länger F; Graf N; Griesinger F; Heukamp LC; Hummel M; Klingebiel T; Hettmer S; Vokuhl C; Merkelbach-Bruse S; Overkamp F; Reichardt P; Scheer M; Weichert W; Westphalen CB; Bokemeyer C; Ivanyi P; Loges S; Schirmacher P; Wörmann B; Bielack S; Seufferlein TTW
    Pathologe; 2021 Feb; 42(1):103-115. PubMed ID: 33258061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
    Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
    Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NTRK fusions are extremely rare in bone tumours.
    Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
    Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
    Jiang YY; Chen H; Xu BL; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
    [No Abstract]   [Full Text] [Related]  

  • 53. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
    Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
    Aref-Eshghi E; Lin F; Li MM; Zhong Y
    Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.
    Lasota J; Chłopek M; Lamoureux J; Christiansen J; Kowalik A; Wasąg B; Felisiak-Gołąbek A; Agaimy A; Biernat W; Canzonieri V; Centonze G; Chmielik E; Daum O; Dubová M; Dziuba I; Goertz S; Góźdź S; Guttmejer-Nasierowska A; Haglund C; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kita P; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ristimäki A; Ryś J; Szostak B; Szpor J; Szumiło J; Teresiński L; Waloszczyk P; Wejman J; Wesołowski W; Miettinen M
    Am J Surg Pathol; 2020 Feb; 44(2):162-173. PubMed ID: 31567189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NTRK-Fusions - A new kid on the block.
    Märkl B; Hirschbühl K; Dhillon C
    Pathol Res Pract; 2019 Oct; 215(10):152572. PubMed ID: 31400924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NTRK fusions in lung cancer: From biology to therapy.
    Harada G; Santini FC; Wilhelm C; Drilon A
    Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.